tirzepatide surpass-5 Effect of Subcutaneous vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The Randomized Clinical Trial Latest Data From SURPASS Trials

Amazing product and amazing service

Aggressive escalation (increasing dose every 2-3 weeks) sometimes produces faster early results but often leads to side effects that interrupt adherence

Bunck, M.D., Ph.D., and Adam Stefanski, M.D., Ph.D., for the SURMOUNT-1 Investigators* Relevant Literature SURMOUNT-1 Trial Relevant Guidelines -SURMOUNT-1 Trial Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guidelines (2015) Drugs may amplify adherence to behavior change and improve physical functioning such that increased physical activity is easier for those who cannot exercise initially

Mounjaros active ingredient, tirzepatide, is known to target both GLP-1 and GIP receptors, which seems to be more effective than Ozempics active ingredient (semiglutide), which only targets GLP-1 receptors, great for certain conditions

In addition to Tirzepatide, we also provide Semaglutide, which has proven effective in reducing weight and controlling blood sugar levels

You should take Tirzepatide (Mounjaro) once a week, at any time of the day